Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Phase 1 Completed 48 enrolled Chipscreen Biosciences, Ltd.

Non-randomizedCrossoverOpen-labelTreatment

Summary

This Phase 1 open label study is being conducted to characterize the pharmacokinetic (PK) and safety profiles of Chiglitazar with Empagliflozin，Atorvastatin and Valsartan in healthy subjects.

Timeline

Start: 2023-02-17
Primary completion: 2023-03-21
Completion: 2023-03-21

Publications

Sheng L, Li X, Yu J, Yang X, Li H, Xu H. Drug-Drug Interaction of Chiglitazar with Empagliflozin, Atorvastatin, and Valsartan: An Open-Label, Single-Center, Self-Control, 3-Period Study. Drug Des Devel Ther. 2026 May 8;20:588573. doi: 10.2147/DDDT.S588573. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atorvastatin	Small molecule	20 mg	Oral
Subject	Chiglitazar	Unknown	48 mg	Oral
Subject	Empagliflozin	Small molecule	10 mg	Oral
Subject	Valsartan	Small molecule	160 mg	Oral

Drug-Drug Interaction Study of Chiglitazar in Healthy Subjects.

Summary

Timeline

Publications

Drugs

Indications